SARS-CoV-2 Variants and Vaccines
Top Cited Papers
- 8 July 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 385 (2), 179-186
- https://doi.org/10.1056/nejmsr2105280
Abstract
Viral variants of concern may emerge with dangerous resistance to the immunity generated by the current vaccines to prevent coronavirus disease 2019 (Covid-19). Moreover, if some variants of concern have increased transmissibility or virulence, the importance of efficient public health measures and vaccination programs will increase. The global response must be both timely and science based.This publication has 20 references indexed in Scilit:
- COVID-19 vaccine trials should seek worthwhile efficacyThe Lancet, 2020
- Temporal Confounding in the Test-Negative DesignAmerican Journal of Epidemiology, 2020
- The Magic of Randomization versus the Myth of Real-World EvidenceThe New England Journal of Medicine, 2020
- Measurement of Vaccine Direct Effects Under the Test-Negative DesignAmerican Journal of Epidemiology, 2018
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventionsBMJ, 2016
- Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trialThe Lancet, 2015
- The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trialsEurosurveillance, 2013
- World War I may have allowed the emergence of “Spanish” influenzaThe Lancet Infectious Diseases, 2002
- Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variationJournal of Clinical Epidemiology, 2001
- SELECTIVE EPIDEMIOLOGIC CONTROL IN SMALLPOX ERADICATION1American Journal of Epidemiology, 1971